Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Single-blind, Controlled, Multicenter Study to Compare the Safety and Immune Response of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With the Safety and Immune Response of One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Adolescents 11 to 17 Years of Age
Conditions
Interventions
MenACWY-CRM conjugate vaccine, adjuvanted
MenACWY-CRM conjugate vaccine, unadjuvanted
+1 more
Locations
3
United States
Rochester, Minnesota, United States
Pittsburgh, Pennsylvania, United States
Seattle, Washington, United States
Start Date
October 1, 2004
Primary Completion Date
March 1, 2006
Completion Date
March 1, 2006
Last Updated
June 28, 2018
Lead Sponsor
Novartis Vaccines
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions